TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02290197

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgical reconstruction of all injured ligaments.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgical reconstruction of all injured ligaments.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hinged External Fixator
Description: Hinged external fixator is used postoperatively for 6 weeks. Early joint mobility in the sagittal plane is encouraged.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cast Immobilization
Description: Cast is used postoperatively for 3 weeks. After this period we use a removable bracing and initiate rehabilitation with physical therapy.
Study: NCT00396214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifeprunox
Description: 52 weeks of fixed oral doses of bifeprunox at 30 mg/day administered as a single dose with 1 week upward titration from 0.25 mg/day dose. Placebo will be used for evening dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Fixed oral dose of quetiapine at 400 mg/day to be administered in divided doses (BID) utilizing a 5-day upward titration from 50 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifeprunox
Description: 52 weeks of fixed oral doses of bifeprunox at 30 mg/day administered as a single dose with 2 week upward titration from 0.25 mg/day dose. Placebo will be used for evening dose.
Study: NCT02274519

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: Arm 1

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Arm 2
Study: NCT00405002

Intervention type: PROCEDURE
Intervention: Helium dilution technique, lung CT scan
Description: Helium dilution technique and lung CT scan
Study: NCT02212197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide acetate FluidCrystal® injection depot

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide acetate FluidCrystal® injection depot

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leuprolide acetate
Study: NCT04030988

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral dexamethasone minipulse
Description: 50 patients will receive mini pulse dexamethasone therapy in a dose of 3 mg/ day for adults or 1.5 mg/day for children on two consecutive days per week plus NB-UVB phototherapy at starting dose of 0.3 J/cm2, at a rate of 3 times per week for 6 months (72 sessions) with gradually increasing increments.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: 50 patients will receive placebo having the same color, form and packaging as the dexamethasone therapy for 6 months plus NB-UVB phototherapy at starting dose of 0.3 J/cm2, at a rate of 3 times per week for 6 months (72 sessions) with gradually increasing increments
Study: NCT01102387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41003
Description: Once daily, topically

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAS189962
Description: Once daily, topically

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAS189961
Description: Once daily, topically
Study: NCT00945698

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement, 10gM
Description: * 140 g of milk-containing LNS (LNS-10gM) 2-weekly (10 g / day) between 6 and 18 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement, 20gM
Description: * 280 g of milk-containing LNS (LNS-20gM) 2-weekly (20 g / day) between 6 and 18 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipid-based Nutrient Supplement, 20gNoM
Description: * 280 g of milk-free LNS (LNS-20gNoM) 2-weekly (20 g / day) between 6 and 18 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement, 40gM
Description: * 560 g of milk-containing LNS (LNS-40gM) 2-weekly (40 g / day) between 6 and 18 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipid-based Nutrient Supplement, 40gNoM
Description: * 560 g of milk-free LNS (LNS-40gNoM) 2-weekly (40 g / day) between 6 and 18 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Maize-soy flour
Description: * No food supplement during the primary trial period (6 to 18 months of age)~* 1 kg fortified maize / soy flour (Likuni phala, LP) 2-weekly (71 g / day) between 18 and 30 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring
Study: NCT01077622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ofatumumab 100 mg, 1000 mg / vial
Description: ofatumumab , 300mg followed by 7 weekly infusions 2000 mg, followed by 4 monthly infusions 2000mg
Study: NCT02542085

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic repair
Description: operative method

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid repair
Description: operative method
Study: NCT01319578

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: K2CG chewing gum
Description: Fasting: Chew gum 15 minutes Post meal: Begin chewing 45 minutes post meal

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: K2CG chewing gum
Description: Fasting: Chew gum 15 minutes Post meal: Begin chewing 45 minutes post meal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: K2CG chewing gum
Description: Fasting: Chew gum 15 minutes Post meal: Begin chewing 45 minutes post meal
Study: NCT03041103

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Product 1
Description: 50 grams of fortified nutritious product from legumes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Product 1
Description: 50 grams of fortified nutritious product from legumes
Study: NCT01656278

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Description: Treatment algorithm based on conventional biochemical/clinical examinations AND MRI of unilateral 2nd to 5th MCP joints and wrist on dominant side. Assessed month 0, 4, 8, 12, 16, 20, 24 with treatment intensification after predefined treatment algorithm in the case of unsatisfactory inflammatory activity, which is defined as the presence of at least one physically swollen joint and DAS28\>3.2 AND/OR MRI-detected bone marrow oedema score \> 0 (RAMRIS-score)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional biochemical and clinical examinations
Description: Treatment algorithm based on conventional biochemical and clinical examinations. Assessed month 0, 4, 8, 12, 16, 20, 24 with treatment intensification after predefined treatment algorithm in the case of unsatisfactory inflammatory activity, which is defined as the presence of at least one clinically swollen joint and DAS28\>3.2
Study: NCT01319578

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: K2CG chewing gum
Description: Fasting: Chew gum 15 minutes Post meal: Begin chewing 45 minutes post meal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: K2CG chewing gum
Description: Fasting: Chew gum 30 minutes Post meal: Begin chewing 30 minutes post meal

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: K2CG chewing gum
Description: Fasting: Chew gum 30 minutes Post meal: Begin chewing 30 minutes post meal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: K2CG chewing gum
Description: Fasting: Chew gum 30 minutes Post meal: Begin chewing 30 minutes post meal
Study: NCT00916968

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard CR-Flex total knee
Description: total knee implant used for joint replacement surgery of the knee

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gender specific CR-Flex
Description: TKA by Gender specific Nexgen CR-Flex
Study: NCT02620384

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Experimental: Placebo
Description: All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first placebo dose is given within six hours of admininstration of first dose of intravenous diuretic. The second placebo dose is given at 24-hours after the first dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Experimental: Metolazone
Description: All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first dose of metolazone is given within six hours of admininstration of first dose of intravenous diuretic The second dose of metolazone is given 24-hours after the first dose.
Study: NCT03260426

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Clear Liquids
Description: Clear liquids on postoperative day zero immediately upon return to the floor and subsequent days' advancement of enteral diet to regular diet is as per discretion of the attending physician.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Regular Solid
Description: Regular diet from postoperative day zero immediately upon return to floor and onwards

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abstats
Description: Intestinal rate measured by Abstats™ in patients offered immediate solid versus clear liquids after colorectal surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abstats
Description: Intestinal rate measured by Abstats™ in patients offered immediate solid versus clear liquids after colorectal surgery
Study: NCT02994758

Intervention type: OTHER
Group type: OTHER
Intervention: Personalised treatment
Description: Treatment based on NGS or DSRT
Study: NCT01763138

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: oral health education
Description: oral health education in the form of a pictorial pamphlet.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: oral health education
Description: oral health education in the form of a pictorial pamphlet.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: reminder phone call
Description: a reminder phone call on oral health instructions would be given to mothers after every one month over a period of three months.
Study: NCT02909829

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed Loop Delivery
Description: Insulin will be delivered by subcutaneous insulin infusion pump. Infusion rates will be changed manually every 10 minutes based on the computer generated recommendation infusion rates, calculated from the glucose levels measured by a real time sensor. The computer generated recommendations are based on a predictive algorithm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed Loop Delivery with Meal Detection Module
Description: Closed Loop Delivery with Meal Detection Module Insulin will be delivered by subcutaneous insulin infusion pump. Infusion rates will be changed manually every 10 minutes based on the computer generated recommendation infusion rates, calculated from the glucose levels measured by a real time sensor. The computer generated recommendations are based on a predictive algorithm with an overlying meal detection module which detects missed meals and will increase insulin infusion rates based on a predictive meal detection algorithm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Pump Therapy
Description: Insulin will be delivered by subcutaneous insulin infusion pump with participants usual infusion rate
Study: NCT00689624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan will be administered at a dose of 150mg/m2 as a 30 min IV infusion on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leukovorin
Description: Leukovorin will be administered at a dose of 200mg/m2 as a 2-hour IV infusion on days 2 and 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered on day 2 at the dose of 65mg/m2 as a 2-hours IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FLUOROURACIL
Description: 5-FLUOROURACIL at the dose of 400mg/m2 as IV bolus and then, 600mg/m2 as a 22-hour continuous IV infusion, on days 2 and 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered at the dose of 500mg/m2 as a 2-hour infusion on day 1 at least one hour before chemotherapy
Study: NCT02787018

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine and Normal saline
Description: Supraclavicular brachial plexus block will be given with 0.5% ropivacaine with 1 ml normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine and Dexamethasone
Description: Supraclavicular brachial plexus block will be given with 0.5% ropivacaine with 4mg (1ml) dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine and Dexmedetomidine
Description: Supraclavicular brachial plexus block will be given with 0.5% ropivacaine with 50 mcg (1ml) dexmedetomidine
Study: NCT04754620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: real time online video visit
Description: Participants have received an online visit by a smartphone application
Study: NCT04403659

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedicine/telemonitoring (TM) suite
Description: The couples patient/caregiver will receive and trained to use a suite of TM instruments including: sphygmomanometer, pulse oximeter, weight scale, thermometer, glucometer, electrocardiograph. During the intervention phase (i.e. from allocation to exit from the study), the caregiver/patient will be asked to measure twice daily, at prespecified times, the following parameters using TM devices: arterial blood pressure, peripheral arterial haemoglobin saturation, tympanic temperature. Body weight will be evaluated once daily.~The TM glucometer and TM electrocardiograph will be used exclusively by healthcare staff in case of patients in need of capillary blood glucose testing and according to clinical needs, respectively. All data will be automatically sent to a central interface and made readily available to physicians and nurses, to enable a prompt clinical response. In case of malfunctioning, a technical support will be ensured.
Study: NCT03070041

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baby-friendly Hospital Initiative
Description: The intervention is Baby-friendly Hospital Initiative as described by WHO and UNICEF. The ten steps to successful breastfeeding will be implemented in the hospital.
Study: NCT01319578

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: K2CG chewing gum
Description: Fasting: Chew gum 30 minutes Post meal: Begin chewing 30 minutes post meal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: K2CG chewing gum
Description: Fasting: Chew gum for 45 minutes Post meal: Begin chewing gum 15 minutes post meal

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: K2CG chewing gum
Description: Fasting: Chew gum for 45 minutes Post meal: Begin chewing gum 15 minutes post meal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: K2CG chewing gum
Description: Fasting: Chew gum for 45 minutes Post meal: Begin chewing gum 15 minutes post meal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: K2CG chewing gum
Description: Fasting: Chew gum for 45 minutes Post meal: Begin chewing gum 15 minutes post meal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: K2CG chewing gum
Description: Fasting: Chew gum for 60 minutes Post meal: Being chewing gum 5 minutes post meal

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: K2CG chewing gum
Description: Fasting: Chew gum for 60 minutes Post meal: Being chewing gum 5 minutes post meal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: K2CG chewing gum
Description: Fasting: Chew gum for 60 minutes Post meal: Being chewing gum 5 minutes post meal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: K2CG chewing gum
Description: Fasting: Chew gum for 60 minutes Post meal: Being chewing gum 5 minutes post meal
Study: NCT04022603

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cyclometer Ergometer
Description: The measurements are carried out on a max effort of 12 minutes on a cyclometer ergometer with a constant load (Motomed viva2 light). A first effort is made with a Venturi type mask whose Inspired Fraction in Oxygen (FiO2) is set for a pulsated oxygen saturation (SpO2) greater than or equal to 85%, and then a second at 2h interval with high-throughput googles (Optiflow) with the corresponding FiO2.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cyclometer Ergometer
Description: The measurements are carried out on a max effort of 12 minutes on a cyclometer ergometer with a constant load (Motomed viva2 light). A first effort is made with a Venturi type mask whose Inspired Fraction in Oxygen (FiO2) is set for a pulsated oxygen saturation (SpO2) greater than or equal to 85%, and then a second at 2h interval with high-throughput googles (Optiflow) with the corresponding FiO2.
Study: NCT04520841

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena TM
Description: A Prevena Plus DuoTM Dressing Kit (KCI) is applied on the surgical wound at the end of surgery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena TM
Description: A Prevena Plus DuoTM Dressing Kit (KCI) is applied on the surgical wound at the end of surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dry dressing
Description: A standard dry sterile dressingwith non-adherent absorbent pad is applied on the surgical wound at the end of surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dry dressing
Description: A standard dry sterile dressingwith non-adherent absorbent pad is applied on the surgical wound at the end of surgery
Study: NCT00816153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PVI-guided fluid management
Description: Peroperative comparison of standard care with PVI-guided fluid management (optimization of the PVI value with fluid loading)
Study: NCT04340466

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT03822377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor orodispersible tablets
Description: Ticagrelor loading dose (180 mg) given as two orodispersible tablets (each of 90 mg), to be dispersed in saliva.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor standard tablets
Description: Ticagrelor loading dose (180 mg) given as two standard coated tablets (each of 90 mg) to be swallowed with water.
Study: NCT03456635

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: guided antimicrobial prophylaxis
Description: During the intervention period, antimicrobial prophylaxis decisions will be guided by a computerized program
Study: NCT01012596

Intervention type: BEHAVIORAL
Intervention: Creighton Model System of Natural Family Planning
Description: Participants will learn the Creighton Model, a standardized method of natural family planning, from FertilityCare Practitioners from established FertilityCare Centers. The learning can be done in-person or long distance.
Study: NCT04882748

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ADAMO
Description: Physical therapy provided with or without the help of a robot

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADAMO
Description: Physical therapy provided with or without the help of a robot
Study: NCT00621946

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Matching Escitalopram

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Active Escitalopram
Study: NCT00557349

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: 40mg dose administered as a suspension or capsule as physician directs daily at bedtime for 14 weeks beginning day of hospital discharge following gastric bypass surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine
Description: 40mg dose administered as a suspension or capsule as physician directs daily at bedtime for 14 weeks beginning day of hospital discharge following gastric bypass surgery.
Study: NCT00721825

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neuroaid
Description: Neuroaid capsules, 4 capsules, three times per day, during one month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Neuroaid matched Placebo
Description: Neuroaid matched placebo 4 capsules three times per day during one month
Study: NCT04017637

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Static resistance training including two arm and two leg movements will be performed twice per week for 12 weeks.
Study: NCT01462825

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: tomato ketchup meal
Description: A single intake of 200 g tomato ketchup together with 200 g white cooked rice.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo meal
Description: Self-prepared vinaigrette matching the qualitative and quantitative macronutrient composition of the tomato ketchup together with 200 g cooked rice resulting in a meal that is isocaloric to the tomato-ketchup meal
Study: NCT01811823

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Trivalent Inactivated Influenza Vaccine
Description: The study vaccine will be the seasonal 2013 un-adjuvanted TIV which is provided as a 0•5 milliliter suspension of split virus mixture of 15 micrograms each of circulating H1N1- like strain, H3N2- like strain and B - like strain.~The WHO recommended vaccine formulation for Southern Hemisphere 2013 Influenza Season contains the following influenza strains:~* A/California/7/2009 (H1N1)pdm-like virus~* A/Victoria/361/2011 (H3N2)-like virus~* B/Wisconsin/1/2010-like virus. (Yamagata lineage)